Overdose prevention study lessons

The Canadian Centre of Recovery Excellence says one of the biggest overdose-prevention trials ever run missed its main target, and that services now need to be built around access barriers, not just awareness. (recoveryexcellence.org) The April 2026 brief reviews the HEALing Communities Study, a $350 million U.S. trial that worked in 67 communities across Kentucky, Massachusetts, New York, and Ohio. The study tested naloxone distribution, safer opioid prescribing, overdose education, stigma-reduction campaigns, and efforts to expand opioid agonist treatment. (recoveryexcellence.org) (nejm.org) Its primary goal was a 40% drop in overdose deaths, but the trial did not produce a statistically significant reduction in overall overdose mortality during the evaluation period. The brief also says the study found no improvement in opioid agonist treatment initiation or retention, even as community attitudes toward opioid use disorder improved. (clinicaltrials.gov) (recoveryexcellence.org) (uc.edu) Opioid agonist treatment is the use of medicines such as methadone or buprenorphine to steady cravings and lower overdose risk. CoRE’s brief says those medicines work when people can actually get them, but education and stigma campaigns alone did not move enough people into care when services stayed hard to reach or hard to keep. (recoveryexcellence.org) The brief lands as Canada’s federal drug strategy still frames the overdose emergency as a mix of harm reduction, treatment, recovery, prevention, and public safety. Health Canada said in its 2023 strategy that more than 38,500 people in Canada had died of apparent opioid toxicity since 2016. (canada.ca) CoRE’s practical recommendations are narrower than the trial’s broad menu of interventions. The brief calls for “real-world reach,” including convenient treatment entry points, virtual options, low-cost medications, and long-acting treatments that cut the burden of daily or weekly clinic visits. (recoveryexcellence.org) It also argues for faster feedback loops. CoRE says jurisdictions should track emergency visits, overdose rates, and deaths in near real time so programs can change course as the illegal drug supply and local service gaps shift. (recoveryexcellence.org) The center is not writing from a neutral distance in Alberta’s policy fight over overdose sites. In March 2026, CoRE published a separate study saying the closure of Red Deer’s overdose prevention site did not increase deaths, emergency department visits, or ambulance calls among identified users over a 26-week follow-up, and that treatment uptake increased as the site prepared to close. (recoveryexcellence.org) (cbc.ca) That Red Deer study drew criticism over scope, follow-up length, and CoRE’s ties to Alberta’s government, which created the center in June 2024 through the Canadian Centre of Recovery Excellence Act. CoRE says its mandate is to produce data-driven policy and practical evaluation for mental health and addiction services. (cbc.ca) (recoveryexcellence.org) The new brief does not call for dropping overdose prevention tools. It says jurisdictions should keep evaluating what works, but spend more effort on the “last mile” — the point where proven treatments fail because patients cannot get in, pay, or stay connected. (recoveryexcellence.org)